# BioCopy

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biocopy

- Industry: Biotechnology
- Headquarters: Basel, Switzerland
- Website: www.biocopy.com/
- Total disclosed funding: $12M
- Latest round: Series A (May 7, 2026)
- Investors on record: 1

## About

Based in Switzerland, BioCopy AG specializes in developing advanced biotherapeutics that target cancer cells with remarkable precision, aiming to enhance therapeutic options in the oncology sector.BioCopy AG, founded in 2016 and headquartered in Basel, Switzerland, focuses on biotherapeutics for cancer treatment. The company raised CHF 9.000 mn in Series A funding in May 2026 from Haute Capital Partners, marking its first funding round. The founder's detailed history is not publicly available, and there is no mention of subsidiaries or parent companies.BioCopy specializes in next-generation biotherapeutics targeting cancer cells with unmatched specificity. The company's offerings include an automated antibody engineering platform that streamlines drug discovery via precision screening and extensive risk assessments, utilizing its ValidaTe technology. They are currently advancing five pHLA-targeted antibody programs addressing solid and liquid tumors, aiming to deliver clinical candidates within the next 3–4 years for markets in North America, Europe, and parts of Asia.BioCopy's revenue model is based on B2B collaborations with biopharmaceutical companies and research institutions, engaging in licensing agreements and co-development deals. Revenue is generated when clients incorporate BioCopy’s products into their drug development pipelines, reflecting the complexity and value of the biotherapeutics developed. Specific pricing structures are customized for each partnership, often under proprietary terms to ensure effective market impact.In May 2026, BioCopy AG raised CHF 9.000 mn in Series A funding from Haute Capital Partners, which will be allocated to support IND-enabling studies for its lead lung cancer candidate entering preclinical development. The company also has plans to expand its reach into new markets, specifically targeting additional regions in Europe and Asia by 2028, enhancing access to its innovative oncology solutions.

## Funding rounds

- Series A, May 7, 2026, $12M — Haute Capital Partners

## Investors

- Haute Capital Partners (https://capitalatlas.ai/funds/haute-capital-partners) — Series A